Quest joins breast cancer gene-testing market

Share this article:

Quest's new BRCA test may loosen Myriad's hold on the genetic cancer testing market. The diagnostics firm is now selling tests for the two cancer genes that are linked to breast and ovarian cancer—BRCA1 and BRCA2—and for which Medicare pays around $3,400 when using Myriad's version. Bloomberg reports that Quest plans on charging $2,500.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.